Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment
Zachary S Clayton,Matthew J Rossman,Sophia A Mahoney,Ravinandan Venkatasubramanian,Grace S Maurer,David A Hutton,Nicholas S VanDongen,Nathan T Greenberg,Abigail G Longtine,Katelyn R Ludwig,Vienna E Brunt,Thomas J LaRocca,Judith Campisi,Simon Melov,Douglas R Seals,Zachary S. Clayton,Matthew J. Rossman,Sophia A. Mahoney,Grace S. Maurer,David A. Hutton,Nicholas S. VanDongen,Nathan T. Greenberg,Abigail G. Longtine,Katelyn R. Ludwig,Vienna E. Brunt,Thomas J. LaRocca,Douglas R. Seals
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.123.21392
IF: 9.8968
2023-08-20
Hypertension
Abstract:Hypertension, Ahead of Print. BACKGROUND AND METHODS:To determine the role of cellular senescence and the senescence-associated secretory phenotype (SASP) in age-related aortic stiffening and endothelial dysfunction, we studied young (6–8 months) and old (27–29 months) p16-3MR mice, which allows for genetic-based clearance of senescent cells with ganciclovir (GCV). We also treated old C57BL/6 N mice with the senolytic ABT-263.RESULTS:In old mice, GCV reduced aortic stiffness assessed by aortic pulse wave velocity (pulse wave velocity, 477±10 versus 382±7 cm/s;P<0.05) to young levels (old GCV versus young vehicle;P=0.35); ABT-263 also reduced aortic pulse wave velocity in old mice (446±9 to 356±11 cm/s;P<0.05). Aortic adventitial collagen was reduced by GCV (P<0.05) and ABT-263 (P=0.12) in old mice. To show an effect of the circulating SASP, we demonstrated that plasma exposure from old-vehicle p16-3MR mice, but not from old- GCV mice, induced aortic stiffening assessed ex vivo (elastic modulus;P<0.05). Plasma proteomics implicated glycolysis in circulating SASP-mediated aortic stiffening. In old p16-3MR mice, GCV increased endothelial function assessed via peak carotid artery endothelium-dependent dilation (old ganciclovir, 94±1% versus old vehicle, 84±2%,P<0.05) to young levels (old GCV versus young vehicle,P=0.98), and endothelium-dependent dilation was higher in old C57BL/6 N mice treated with ABT-263 versus vehicle (96±1% versus 82±3%;P<0.05). Improvements in endothelial function were mediated by increased nitric oxide bioavailability (P<0.05) and reduced oxidative stress (P<0.05). Circulating SASP factors related to nitric oxide signaling were associated with higher nitric oxide–mediated endothelium-dependent dilation following senescent cell clearance.CONCLUSIONS:Cellular senescence and the SASP contribute to vascular aging, and senolytics hold promise for improving age-related vascular function.
peripheral vascular disease